COMPANY

Maxwell Biosciences

Also known as Maxwell Biosciences, Inc. · 3 sources

Keywords: infectious disease

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $20M · announced Aug 5, 2025 Company release ↗
Source quote
- Aug 5, 2025 · Company release ↗
  “– Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today announced the closing of its $20 million financing round”

Raises announced in these releases: $20M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Dec 17, 2025 Partnership Partnership / licensing announced Dec 17, 2025. Source: company's own press page. source ↗
Aug 5, 2025 Raise Private equity round: $20M (total, as published), announced Aug 5, 2025. Source: company's own press page. source ↗
Aug 5, 2025 Raise Undisclosed round · $20M source ↗

Raised: $20.0M. Last 2 years.

Aug 5, 2025 Private equity round: $20M (total, as published), announced Aug 5, 2025. Source: company's own press page. source ↗
Dec 17, 2025 Partnership / licensing announced Dec 17, 2025. Source: company's own press page. source ↗

Annual award amounts. Total $257K.

Aug 27, 2021 NIH award 1R41DC020077-01 FY2021: $256,538 awarded for that fiscal year; activity R41 (STTR); PI KIRSHENBAUM, KENT W; recipient as written: MAXWELL BIOSCIENCES, INC., AUSTIN, TX. Synthetic Antimicrobial Peptoids for source ↗